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ABSTRACT
An attractive molecular target for novel anti-cancer therapies is the 
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
pathway which is commonly deregulated in many types of cancer. Nevertheless, the 
effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component of immune 
responses, have been seldom explored. In this study we investigated the effects on 
human CD4+ T-cells of a panel of PI3K/Akt/mTOR inhibitors: BGT226, Torin-2, MK-
2206, and ZSTK474. We also assessed their efficacy against two acute leukemia T 
cell lines. T lymphocytes were stimulated with phytohemagglutinin. Inhibitor effects 
on cell cycle and apoptosis were analyzed by flow cytometry, while cytotoxicity was 
assessed by MTT assays. In addition, the activation status of the pathway as well as 
induction of autophagy were analyzed by Western blotting.
Quiescent healthy T lymphocytes were unaffected by the drugs whereas mitogen-
stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, 
caspase-dependent apoptosis, and dephosphorylation of key components of the 
signaling pathway. Autophagy was also induced in proliferating lymphocytes and in 
JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine 
or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is a 
protective mechanism.
Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve 
lymphocyte viability. This is a valuable result to be taken into account when selecting 
drugs for targeted cancer therapy in order to minimize detrimental effects on immune 
function.
INTRODUCTION
The phosphatidylinositol-3 kinase/Akt/mTOR 
(PI3K/Akt/mTOR) signal transduction pathway is 
activated by several stimuli regulating cell proliferation 
and survival, translation, autophagy and metabolism. 
Several members of the PI3K/Akt/mTOR cascade play 
crucial roles in maintaining cell homeostasis under normal 
physiological conditions [1].
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PI3K comprises a family of lipid kinases which 
phosphorylate the 3-OH group of inositol lipids. They are 
classified into Class I, II, and III based on primary structure 
and regulation. Class I PI3Ks are heterodimeric enzymes, 
displaying a catalytic and a regulatory subunit. The catalytic 
subunits comprise p110α, p110β, p110γ, and p110δ, which 
associate in different ways with the regulatory subunits 
(p85α, p85β, and p55γ, p101, p84, and p87PIKAP) [2].
Akt requires phosphorylation of both Ser473 and 
Thr308 amino acidic residues to be fully activated and 
regulates several downstream, processes including positive 
activation/regulation of mTOR functions [3].
mTOR is a 289-kDa serine/threonine protein kinase, 
which regulates cell growth. mTOR is the catalytic subunit 
of two multi-protein complexes: complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2).
mTORC1 is responsive towards growth factors, 
nutrients, energy, or oxidative stress and phosphorylates 
4E-BP1 and S6K which are important for protein 
translation. mTORC2 phosphorylates Akt at the Ser473 
residue for complete activation of the PI3K/Akt/mTOR 
pathway. Other downstream substrates of mTORC2 
include PKC [4, 5].
T-cell acute lymphoblastic leukemia (T-ALL) 
is a malignant disease of T lymphocytes progenitors, 
characterized by the accumulation of immature 
undifferentiated thymocytes that acquired multiple genetic 
aberrations. This results in a poor prognosis, especially 
for relapsed patients [6]. Aberrant regulation of the PI3K/
Akt/mTOR axis often confers a proliferative advantage to 
tumor cells and contributes to the development of drug-
resistance mechanisms.
At present only class I PI3Ks have been shown to be 
associated with cancer: indeed PIK3CA, the gene which 
encodes for p110α PI3K, is mutated in a variety of tumor 
types [7–9]. Mutations of the p85 subunit have also been 
shown to be oncogenic [10, 11].
The PI3K/Akt/mTOR signaling pathway is 
frequently up-regulated in T-ALL. This is due to several 
causes, including phosphorylation, oxidation and gene 
mutation/deletion, which affect PTEN phosphatase 
function [12, 13].
Thus, targeting the PI3K/Akt/mTOR axis represents 
an attractive novel therapeutic strategy for T-ALL. 
However, which drug against one or more members of this 
signaling network can achieve the greater efficacy is still 
an open question.
To address this issue we employed a 
pharmacological approach aimed to compare the efficacy 
of four drugs, one targeting mTORC1/C2 (Torin-2) [14, 
15], one against PI3K/mTORC1/C2 (NVP-BGT226) 
[16, 17], one targeting Akt (MK-2206) [18–21], and the 
fourth one directed against all the class I PI3K isoforms 
(ZSTK474) [22–24].
Only a limited number of studies have analyzed 
the impact of PI3K/Akt/mTOR network inhibitors on 
human T-cells. The few published data have been mainly 
focused only on PI3K inhibitors, such as wortmannin and 
LY294002 [25] or pan class I PI3K inhibitors [26] or drugs 
targeting selectively p110δ [27, 28] or p110α [24].
Drugs targeting the PI3K/Akt/mTOR cascade can 
interfere with diverse biologic processes also in healthy 
cells, thus rising concerns about their use in therapeutics. 
In particular, it is essential to gain knowledge about 
their effect on immune cells, as it would be desirable to 
preserve patient’s immunity.
The aim of this study was to analyze the effect of 
the four above mentioned drugs in human primary CD4+ 
T-cells. most of these inhibitors are currently being tested 
in clinical trials. We have assessed the anti-tumor activity 
of NVP-BGT226 (BGT226), Torin-2, MK-2206 and 
ZSTK474 in human T-ALL cells and studied their effects 
on healthy CD4+ T-cell, induced or not to proliferate.
Our findings suggested that, to minimize off-target 
effects and to benefit from the optimal response, selective 
inhibitors targeting the PI3K/Akt/mTOR may represent a 
new promising treatment for T-ALL patients, since they 
showed a strong cytotoxicity against leukemic T-cells or 
T-lymphocytes stimulated to proliferate, whereas they did 
not compromise viability of quiescent healthy CD4+ T 
lymphocytes.
RESULTS
Activation status of PI3K/Akt/mTOR pathway 
in healthy CD4+ T lymphocytes and T-ALL cell 
lines
By Western blot analysis, we wanted to evaluate 
the baseline levels of some key proteins involved in the 
PI3K/Akt/mTOR axis in both unstimulated and stimulated 
healthy CD4+ T lymphocytes and in T-ALL cells (MOLT-
4 and JURKAT cell lines). We decided to study CD4+ 
cells as they are helper cells that play important roles for 
regulating immunological responses [29].
Stimulated T lymphocytes, MOLT-4 and JURKAT 
cells showed a relevant phosphorylation at Ser473 and 
Thr308 of Akt and at Ser235/236 of ribosomal protein S6 
kinase, a readout of mTORC1 activity. The same cell types 
also displayed mTOR phosphorylation at Ser2448 and 
Ser2481 residues, readout for mTORC1 and mTORC2, 
respectively. The phosphorylation was not evident in 
unstimulated CD4+ T lymphocytes (Figure 1).
BGT226, Torin-2, MK-2206 and ZSTK474 
are cytostatic and cytotoxic to stimulated 
T lymphocytes and T-ALL cell lines
BGT226 is an ATP-competitive dual PI3K/
mTORC1/2 inhibitor used for treatment of advanced solid 
tumors [30, 31]. As previously reported by our group, it 
was cytotoxic to a panel of hepatocarcinoma cell lines, 
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under both normoxia and hypoxia conditions [32]. Torin-2 
potently targets mTORC1/2, and is an effective inhibitor 
of ATM, ATR and DNA-PK [14].
The efficacy of MK-2206 as well as ZSTK474 
have been tested in various preclinical models of human 
cancers, including leukemias [3, 19, 22, 33–36].
To determine how these inhibitors could affect 
the viability of the primary CD4+ T lymphocytes (both 
unstimulated and stimulated) and T-ALL cells, we 
performed MTT assays. Cells were incubated for 48 h 
with the inhibitors, and then cell survival was analyzed 
(Figure 2A and Table 1). Except for the unstimulated T 
lymphocytes, BGT226 and the mTORC1/2 inhibitor 
Torin-2 turned out to be the most powerful drugs in 
these cells. For unstimulated T lymphocytes, there was 
no relevant inhibition for both drugs (IC50 > 2 μM). For 
BGT226, cell viability impairment was more evident 
in T-ALL cell lines, with IC50 values of 0.08 μM for 
JURKAT, 0.06 μM for MOLT-4 and 1.61 μM for 
stimulated T lymphocytes. Similar results were obtained 
with Torin-2, with IC50 values of 0.1 μM for JURKAT and 
MOLT-4 and 1.8 μM for stimulated T-cells.
Regarding MK-2206, the cells displayed higher 
values of IC50 (> 2 μM) except for MOLT-4 cells with 
an IC50 of 1.58 μM. For ZSTK474 the same resistance 
for the primary T lymphocytes was observed, while in 
MOLT-4 and JURKAT cell lines the sensitivity of the drug 
was evident, with IC50 values of 0.52 μM and 0.95 μM, 
respectively. The IC50 of stimulated T lymphocytes was 
> 2 μM (Table 1).
To further assess the cytotoxicity of inhibitors 
targeting PI3K/Akt/mTOR, we analyzed the changes in 
cell viability using flow cytometry after treatment with 
1μM of each drug for 48 h. Compared to MK-2206 
and ZSTK474, BGT226 and Torin-2 displayed higher 
cytotoxic effect on stimulated T lymphocytes, MOLT-4 
and JURKAT cells. None of the drugs affected the viability 
of unstimulated CD4+ T lymphocytes (Figure 2B). For all 
these reasons, for the subsequent experiments we decided 
to test only BGT226 and Torin-2.
Considering the important role of the PI3K/
Akt/mTOR signaling cascade in regulating cell 
proliferation [37], we investigated the effect of the drugs 
on cell cycle progression. Cells were treated with the two 
most effective drugs (BGT226 and Torin-2) for 24 h and 
stained with Propidium Iodide (PI) for flow cytometric 
analysis. A concentration dependent increase of cells in the 
G0/G1 phase of the cell cycle and a concomitant decrease 
in cells of both S and G2/M phase were observed (Figure 
3). The increase was highly significant in stimulated T 
lymphocytes, MOLT-4 and JURKAT cells, whereas did 
not occur in unstimulated T lymphocytes.
BGT226 and TORIN-2 down-regulate the 
PI3K/Akt/mTOR pathway in stimulated CD4+ T 
lymphocytes and T-ALL cells
To determine whether BGT226 and Torin-2 could 
affect factors that promote cell survival, stimulated T 
lymphocytes, MOLT-4 and JURKAT cells were treated 
Figure 1: Expression and phosphorylation status of Akt, mTOR and the S6 downstream target in primary (unstimulated 
and stimulated) CD4+ T lymphocytes and T-ALL cell lines. Western blot analysis of primary T lymphocytes and T-ALL cell lines 
to detect the expression and phosphorylation levels of Akt, mTOR, and S6 protein. Twenty-five μg of protein were blotted on each lane. 
β-actin was revealed as loading control.
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with increasing concentrations of BGT226 and Torin-2 
for 2 h and then analyzed by Western blot (Figure 4). 
The inhibition of mTORC2 had a readout in Ser473 Akt 
dephosphorylation and it was observed in all cell types 
treated with BGT226 and Torin-2 starting from the 
lowest concentrations. Thr308 Akt was dephosphorylated 
by both drugs, as was GSK3β Ser21/9, an Akt 
substrate. The mTORC1 substrate S6 was completely 
dephosphorylated on Ser235/236 residue, already at the 
lowest concentrations of BGT226 and Torin-2. Both drugs 
downregulated the phosphorylation levels of mTOR at 
both Ser2448 and Ser2481 residues [38].
BGT226 and TORIN-2 induce autophagy
Autophagy plays a very important role in cell 
physiology, either as a form of cell death or as a protective 
mechanism against apoptosis [39, 40]. Therefore, there is a 
growing interest on the pharmacological approaches aimed 
to regulate autophagy, which represent a new area for the 
development of therapeutics protocols. Moreover, over the 
last few years various papers described the occurrence of 
autophagy in acute leukemia cells [reviewed in 42]. To find 
out if BGT226 and Torin-2 could induce autophagy, we 
analyzed the expression levels of microtubule-associated 
Figure 2: Cytotoxicity of BGT226, Torin-2, MK-2206 and ZSTK474 in primary T lymphocytes, MOLT-4 and JURKAT 
cell lines. A. MTT assays of primary T lymphocytes and T-ALL cell lines treated with increasing concentrations of BGT226, Torin-2, 
MK-2206 and ZSTK474 for 48 h. SD was less than 7%. One representative experiments of three is shown. B. Viability of primary T 
lymphocytes, MOLT-4 and JURKAT cell lines treated for 48 h with 1 μM BGT226, Torin-2, MK-2206 and ZSTK474. Asterisks indicate 




protein 1 light chain 3 LC3A/B I (non-lipidated form) and 
of its conjugated form LC3A/B II (lipidated). After 24 h 
of treatment with BGT226 and Torin-2, the unstimulated 
T lymphocytes showed no expression of LC3A/B II 
which, in contrast, increased gradually in a concentration 
dependent manner, for both drugs, especially in MOLT-
4 and JURKAT cells (Figure 5A). We also analyzed 
the expression of p62, another marker of autophagy. 
p62 levels decreased in response to drug treatments in 
stimulated CD4+ lymphocytes and leukemic cell lines, but 
remained unchanged in quiescent T-cells (Figure 5A).
To establish whether autophagy was either a 
cell death or survival mechanism, we employed the 
autophagy inhibitor 3-Methyladenine (3-MA), which 
inhibits autophagy by blocking class III PI3K [41]. We 
also used Bafilomycin A1, another autophagy inhibitor, 
to further assess the mechanism of drug cytotoxicity. We 
treated stimulated T lymphocytes and JURKAT cells with 
BGT226, Torin-2, 3-MA or Bafilomycin A1 alone and 
in combination for 24 h. Results showed that 3-MA or 
Bafilomycin A1 alone did not affect cell viability, even 
at high concentrations (10 μM or 4 μM, respectively). 
On the other hand, when 3-MA or Bafilomycin A1 were 
administered with 0.25 μM BGT226 or Torin-2, the cells 
became more sensitive to the cytotoxic effect of both 
drugs (Figure 5B and 5C). These findings highlighted a 
protective role of autophagy from cytotoxicity induced by 
BGT226 and Torin-2 in stimulated T-lymphocytes and in 
JURKAT cell line.
Apoptosis is required for mediating BGT226 and 
Torin-2 cytotoxicity
Previous studies documented that in T-ALL cells 
BGT226 could induce apoptosis [42]. In addition, our 
recent results demonstrated that Torin-2 is effective in 
Pre-B precursor-ALL cells [43]. In order to establish 
whether decreased viability was due to apoptosis, 
unstimulated and stimulated T lymphocytes as well as 
MOLT4 and JURKAT cell lines, were incubated with 
increasing concentrations of BGT226 and Torin-2 for 
24 h, then Western blot was performed for analyzing the 
expression levels of poly(ADP-ribose)polymerase (PARP). 
The unstimulated T lymphocytes displayed no evidence 
for apoptosis. In contrast, significant cleavage of PARP 
was observed, especially in stimulated T lymphocytes, but 
also in MOLT-4 and JURKAT cells (Figure 6A).
To elucidate whether caspases were involved in the 
apoptotic activity of BGT226 and Torin-2, we analyzed the 
effect of z-VAD-fmk, a broad-spectrum caspase inhibitor 
whose activity had been checked already in different 
cancer cells [44, 45]. We administrated z-VAD-fmk alone 
and in combination with BGT226 or Torin-2 for 24 h in 
stimulated T lymphocytes and MOLT-4 cells, then cells 
were analyzed by MTT assays. Results showed that 
z-VAD-fmk (25 μM) alone had no relevant effect on cell 
viability, however when combined with BGT226 and 
Torin-2, it significantly inhibited apoptosis mediated by 
both drugs, in stimulated T lymphocytes and MOLT-4 
cells. Thus, these findings indicated that BGT226 and 
Torin-2 induced a caspase-dependent apoptosis (Figure 
6B).
We also measured caspase 3/7 activation by 
enzymatic cleavage of the profluorescent substrate 
rhodamine 110, bis-N-CBZ-L-aspartyl-Lglutaml- L-valyl-
L-aspartic acid amide (Z-DEVD-R110), with release of 
the intensely fluorescent rhodamine 110-cleaving group 
[46]. The activity of caspase 3/7 was increased after 
drug treatment and was down-modulated by z-VAD-fmk 
(Figure 6C).
Furthermore, we studied drug-induced apoptosis 
using Annexin-V staining in stimulated T lymphocytes, 
MOLT-4 and JURKAT cell lines treated with BGT226 
or Torin-2 for 24 h. BGT226 effect was more relevant in 
MOLT-4 and stimulated T lymphocytes than in JURKAT 
cells, while the effect of Torin-2 was stronger in MOLT-
4 and JURKAT cells than in stimulated T lymphocytes 
(Figure 7A). The percentages of live, early and late 
apoptotic cells in response to treatment with BGT226 and 
Torin-2 (0.1, 0.25 and 0.5 μM) are shown in Figure 7B.
DISCUSSION
Although preclinical studies have demonstrated that 
inhibition of PI3K/Akt/mTOR axis could be an effective 
strategy for targeted therapy of T-ALL [47, 48], it is still 
unclear which is the best target in this highly complex and 
branched signaling network. Pharmaceutical companies 
Table 1: IC50 values of cells treated for 48 hours with different drugs
 BGT226 Torin-2 MK2206 ZSTK474
UNSTIMULATED
T-Lymphocytes >2.0 >2.0 >2.0 >2.0
STIMULATED
T-Lymphocytes 1.61 1.8 >2.0 >2.0
MOLT-4 0.06 0.1 1.58 0.52
JURKAT 0.08 0.1 >2.0 0.95
Values are expressed in μM
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have synthesized a wide array of drugs, that target 
different components of this signaling parthway [49, 50]. 
This allows to envisage different strategies based on one 
side on the use of selective inhibitors displaying reduced 
adverse effects, and on the other side pan-inhibitors 
expected to exert a greater efficacy.
It has been recently documented that PI3K inhibitors 
were the most effective in inhibiting leukemic cell 
proliferation and survival in a panel of T-ALL human 
Figure 3: BGT226 and Torin-2 affect cell cycle in primary T lymphocytes, MOLT-4 and JURKAT cell lines. Unstimulated 
and stimulated T lymphocytes, MOLT-4 and JURKAT cells were treated with increasing concentrations of BGT226 and Torin-2 for 24 h. 
CTRL, control (untreated) cells. SD was less than 10%.
Figure 4: Expression and phosphorylation status of mTOR, Akt and their downstream targets in primary T lymphocytes 
and T-ALL cell lines. Western blot analysis of phosphorylated and total Akt, mTOR and their substrates GSK3β and S6 in stimulated 
T lymphocytes, MOLT-4 and JURKAT cells treated for 2 h with increasing concentrations of BGT226 and Torin-2. For all experiments 
twenty-five μg of protein was blotted on each lane. β-actin served as loading control.
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cell lines, irrespectively of PTEN status. These findings 
strongly supporting clinical application of class I PI3K 
pan-inhibitors rather than dual γ/δ or single-isoform 
inhibitors for treatment of the majority of T-ALL patients 
[51].
Nevertheless, the functions of the immune system 
cells could be impaired by these drugs. Here we evaluated 
the effects on human healthy CD4+ T-cells of four 
PI3K/Akt/mTOR inhibitors used as anticancer agents, 
to explore how these treatments could affect the patient 
immunological status.
No cytotoxic effects were displayed by the drugs 
on unstimulated CD4+ T lymphocytes, whereas all the 
inhibitors and particularly BGT226 and Torin-2 reached 
IC50 values in the nanomolar range in T-ALL cells. 
In consideration of these findings, we performed the 
following sets of experiments using only BGT226 and 
Torin-2.
As to the cell cycle, since the unstimulated CD4+ T 
lymphocytes are mostly in a quiescent status, the drugs did 
not exert any effect, thus demonstrating the selectivity of 
the inhibitors.
In contrast, in either stimulated CD4+ T-lymphocytes 
or MOLT4 and JURKAT cell lines, BGT226 and Torin-2 
induced a concentration-dependent accumulation in the 
G0/G1 phase, and a concomitant decrease in S and G2-M 
phases, as reported by others [52–54].
As shown by Western blot, Torin-2 and BGT226 
effectively blocked the phosphorylation of Akt Ser 473 
and Thr308, GSK3β Ser21/9, mTORC1 Ser2448 and 
Figure 5: BGT226/Torin-2 induced autophagy in unstimulated, stimulated T lymphocytes and T-ALL cell lines. A. 
Western blot analysis of primary T lymphocytes and T-ALL cell lines treated for 24 h with increasing concentrations of BGT226 and 
Torin-2. An increase of expression of fast-migrating (lipidated) LC3A/B and a reduction of p62 in stimulated T lymphocytes, MOLT-4 
and JURKAT cells is shown. Twenty-five μg of protein were blotted on each lane. β-actin documented equal lane loading. B. MTT assay 
documenting the effect of the autophagy inhibitor 3-MA (3-Methyladenine) on the viability of stimulated T lymphocytes and JURKAT 
cells treated for 24 h with BGT226 and Torin-2. C. MTT assay documenting the effect of the autophagy inhibitor Bafilomycin A1 on the 
viability of stimulated T lymphocytes and JURKAT cells treated for 24 h with BGT226 and Torin-2. Results are the mean of three different 
experiments ± SD. Asterisks indicate significant differences with respect to untreated cells (*p< 0.05).
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mTORC2 Ser2481. Furthermore, an mTORC1 
downstream target, S6 protein, was fully dephosphorylated 
in both stimulated T lymphocytes and T-ALL cells.
Healthy unstimulated CD4+ T lymphocytes did not 
display induction of autophagy as documented by Western 
blot analysis of LC3A/B. Stimulated T lymphocytes 
appeared more sensitive to induction of autophagy when 
compared to unstimulated ones. We also documented 
that in leukemic cells the induction of autophagy was 
a protective mechanism, since cells incubated with 
autophagy inhibitors were less viable. Similar results were 
obtained in stimulated T lymphocytes.
The drugs also induced apoptosis in both stimulated 
T lymphocytes and leukemic cells. On the contrary, resting 
T lymphocytes did not undergo apoptosis. The apoptotic 
cell death was dependent on caspase activity. Therefore, 
apoptosis is one of the mechanisms that explain the 
cytotoxicity of these drugs.
It is now assumed that tumor growth and survival 
can be either promoted or restrained by immune system 
Figure 6: BGT226/Torin-2 induced autophagy in unstimulated, stimulated CD4+ T lymphocytes and T-ALL cell 
lines. A. Western blot analysis documenting the increase of PARP cleavage in stimulated T lymphocytes and T-ALL cell lines treated for 
24 h with increasing concentrations of BGT226 and Torin-2. Twenty-five μg of protein was blotted on each lane. β-actin served as loading 
control. B. MTT assays after BGT226 and Torin-2 treatment, alone and in combination with the pan caspase inhibitor z-VAD-fmk, in 
stimulated T lymphocytes and MOLT-4 cells. The analysis was performed after 24 h of treatment with BGT226 and Torin-2 at 0.25 μM 
and z-VAD-fmk at 25 μM. C. enzymatic cleavage of the profluorescent substrate Z-DEVD-R110, with release of the intensely fluorescent 
rhodamine 110-cleaving group, after BGT226 and Torin-2 treatment, alone and in combination with the pan caspase inhibitor z-VAD-fmk, 
in stimulated T lymphocytes and MOLT-4 cells. The analysis was performed after 24 h of treatment with BGT226 and Torin-2 at 0.25 μM 
and z-VAD-fmk at 25 μM. Results are the mean of three different experiments ± SD. Asterisks indicate significant differences with respect 
to untreated cells (*p< 0.05).
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Figure 7: Flow cytometric analysis of drug-induced apoptosis. A. Analysis of Annexin-V positive cells after BGT226 and 
Torin-2 treatment using the Muse™ Cell Analyzer in stimulated CD4+ T lymphocytes, MOLT-4 and JURKAT cells. The analysis was 
performed after 24 h of treatment with increasing concentrations of the drugs. Results are the mean of three different experiments ± SD. 
B. Flow cytometric plots of Annexin V-FITC/PI stimulated T lymphocytes, MOLT-4 and JURKAT cells, treated with 0.5 μM BGT226 and 
Torin-2. One representative of three different experiments that yielded similar results is shown.
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cells [55, 56]. Therefore, it is critical to define whether 
novel anti-tumor drugs may impact on cells of the immune 
system. The ideal targeted therapy should specifically 
hit cancer cells and enhance anti-tumor immunity while 
preserving patient immunity [24].
It has been demonstrated that lymphocyte functions 
were minimally affected by p110α inhibition both in 
vitro and in vivo. Although p110α inhibition partially 
diminished Akt activation, it is likely that selective p110α 
inhibitors will be less immunosuppressive in vivo than 
p110δ or pan PI3K class I inhibitors [24].
Natural killer cell-mediated cytotoxicity as well as 
antibody dependent cellular cytotoxicity against tumor 
cells were significantly impaired by pan class I PI3K 
inhibitors, whereas p110α selective drugs had no effect 
[51, 57].
Other authors have shown recently that single 
inhibitors of class I PI3K isoforms in T-lymphocytes 
exerted a less potent impairment of T-cell activation than 
simultaneous inhibition of two or more isoforms [54]. 
These results suggest that complete blockade of class I 
PI3K activity strongly impairs T lymphocyte proliferation 
and activation in vitro.
In addition, it has been demonstrated that two ATP-
competitive PI3K pan-class I inhibitors, PX-866 and 
BKM120, showed differences in their ability to block 
T-lymphocytes proliferation and IL-2 secretion [26].
Nevertheless, these investigations were restricted 
only to pan class I PI3K isoform inhibitors and did not 
explore other drugs, such as Torin-2 and BGT226, which 
target to additional components of the PI3K/Akt/mTOR 
axis.
Therefore our data expanded the concept that 
targeted therapies, using different drugs against molecules 
at different levels of the PI3K/Akt/mTOR cascade, 
may be effective against tumor cells harboring aberrant 
upregulation of this signaling network, without affecting 
at the same time the immune system.
Given the commonly observed dysregulation of 
PI3K/Akt/mTOR pathway in T-ALL, the various types of 
single or dual pathway inhibitors under development might 
be effective in T-ALL treatment, provided that they do 
not affect the immune system. Therefore, the study of the 
effects of PI3K/Akt/mTOR inhibition not only in tumor 
cells, but in immune cells as well, may lead to selection 
of treatments that, while efficiently targeting deregulated 
PI3K/Akt/mTOR signals in tumor cells, preserve normal 




RPMI-1640 medium, fetal bovine serum (FBS), 
penicillin and streptomycin were purchased from Lonza 
Milano SRL (Milan, Italy). Torin-2, NVP-BGT226, MK-
2206 and ZSTK474 were obtained from Selleck Chemicals 
(Houston, TX, USA). For cell viability determination, 
Cell Proliferation Kit I (MTT) was purchased from Roche 
Applied Science (Basel, Switzerland). Annexin V/7-
ADD detection kit and cell cycle kits were from Merck-
Millipore (Darmstadt, Germany). For Western blot, 
antibodies to total Akt-1, Ser473 p-Akt-1 and Thr308 
p-Akt-1 were from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), while all the other antibodies were from Cell 
Signaling Technology (Danvers, MA, USA), including the 
rabbit secondary antibody. The mouse secondary antibody, 
z-VAD-fmk, 3-Methyladenine (3- MA), Bafilomycin 
A1, Ficoll-Paque Plus and phytohemagglutinin were 
purchased from Sigma Aldrich (Milan, Italy). Dynabeads 
T-cell separation kit was from Invitrogen life Technologies 
(Monza MB, Italy). Signals were detected using ECL Plus 
reagent from Perkin Elmer (Boston, MA, USA).
Cell culture and Western blot analysis
Cell lines
T-acute lymphoblastic leukemia cell lines obtained 
from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (Braunschweig, Germany). JURKAT 
and MOLT-4 were maintained in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 100 units/ml penicillin and 100 mg/ml 
streptomycin at a density of 0.5 to 2 x 106 cells/ml and 
were incubated at 37°C with 5% CO2.
Primary samples
Peripheral Blood CD4+ T lymphocytes from healthy 
donors were obtained with informed consent according to 
institutional guidelines and isolated with Ficoll-Paque and 
magnetic beads labelling protocols (Dynabeads, Monza 
MI, Italy). Whole blood or buffy coat were diluted with 
PBS containing 0.1% BSA and 0.6% Na-citrate or 2 mM 
EDTA (without Ca2+ and Mg2+) in ratio 1:1. Thirty-five 
ml of the diluted sample were layered over 15 ml of Ficoll-
Paque medium and centrifuged at 600 g for 40 minutes 
at 20°C. The peripheral blood mononuclear cell (PMNC) 
layer was transferred to centrifuge tube containing three 
volumes of PBS and centrifuged at 100 g for 10 minutes 
at 20°C. This step was repeated twice, supernatant was 
discarded and cells were suspended in complete RPMI-
1640 medium.
500 μl PMNC were transferred into a test tube, at 
a density of 5 x 107 cells/ml supplemented with100 μl of 
heat inactivated FBS and antibody mix and incubated at 
4°C for 20 minutes. Followed by addition of 4 ml isolation 
buffer and centrifuged at 350 g at 4°C for 8 minutes. 
The supernatant discarded, and the pelleted cells were 
suspended in 500 μl of isolation buffer, added with 500 
μl of pre-warmed dynabeads and incubated for 15 min at 
20°C. The cells bound to beads were resuspended using 
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4 ml isolation buffer. The supernatant containing the 
human CD4+ T lymphocytes was obtained by placing the 
resuspended cells in magnet for 2 minutes. The human 
CD4+ T lymphocytes were grown in complete RPMI-1640 
medium with 10μg/ml phytohemagglutinin at a density of 
1 x 106 cells/ml, in a CO2 incubator at 37°C for 24 h [58, 
59].
Western blot
The cells were homogenized for 30 min in cold 
lysis buffer (50 mM Hepes pH 7.5, 5 mM EDTA pH 
8.0, 10 mM MgCl2, 150 mM NaCl, 50 mM NaF, 20 
mM β-glicerophosphate, 0.5% NP40, 0.1 mM sodium 
orthovanadate, 1 mM PMSF, 1 mM DTT) containing the 
protease inhibitor cocktail obtained from Roche Applied 
Science Basel, Switzerland. Lysates were centrifuged in 
a Microfuge for 10 min at 4°C and 25 μg of solubilized 




Diphenyltetrazolium Bromide) assays were performed to 
assess the sensitivity of cells to drugs, as described [62, 
63].
Cell cycle and apoptosis analysis
Cell cycle analysis was performed using the Muse™ 
Cell Analyzer (Merck Millipore, Milan, Italy). Cells 
were harvested after 24 h of treatment with the drugs, 
centrifuged at 300 g for 5 minutes and washed with 1x 
PBS. The cells were then fixed with 70% cold ethanol for 
3h at -20°C, centrifuged at 300 g for 5 min and washed 
with 1x PBS. Each sample was then resuspended in 200 
μl of Muse™ Cell Cycle reagent, incubated in the dark for 
30 min at room temperature, and analyzed according to the 
manufacturer’s instructions. The analysis of apoptosis was 
performed by Annexin V/7-ADD-Assay. The cells treated 
with increasing concentrations of BGT226 or Torin-2 were 
harvested after 24 h. The cell suspension was labeled in 
the dark for 20 min with an equal volume (100 μl) of the 
Muse™ Annexin-V Dead cell reagent (Merck Millipore). 
Subsequently, quantitative detection of Annexin-V/7-
AAD positive cells was performed using the Muse™ Cell 
Analyzer.
Caspase-3/-7 activity assay
Caspase activity was measured with the Apo-
One Homogeneous Caspase 3/7 assay kit (Promega 
Corporation, Madison, WI, USA), according to the 
manufacturer’s instructions. The induction of apoptosis 
and associated activation of caspases 3 and 7 were 
measured by enzymatic cleavage of the profluorescent 
substrate rhodamine 110, bis-N-CBZ-L-aspartyl-Lglutaml- 
L-valyl-L-aspartic acid amide (Z-DEVD-R110), which 
releases the intensely fluorescent rhodamine 110-cleaving 
group. Cells were seeded at a density of 1×105/ml and 
incubated in a 96-well plate in the presence or absence 
of drug for 48 h. For cells treated with a combination of 
z-VAD-fmk and drugs, they were initially treated with 
z-VAD-fmk for 4 h prior to the addition of drugs. 100 
μl of the homogeneous caspase-3/-7 reagent was added 
to each well and the reaction mixture was incubated for 
2 h at room temperature. Fluorescence was measured 
at an excitation wavelength of 485 nm and an emission 
wavelength of 538 nm. Results are expressed as relative 
fluorescence units (RFU).
Statistical evaluation
The data are presented as mean values from three 
separate experiments ± SD. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of P<0.05 vs 
control samples [64].
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